Trio Health presents novel HBV, HCV therapy findings at The Liver Meeting

Trio Health presented results from four studies at The Liver Meeting 2019 that showed novel outcomes in patients treated for hepatitis B with Vemlidy or hepatitis C with Vosevi.“Since our initial HCV studies in 2013, we’ve observed repeating themes across diseases where new, more efficacious, and safer therapies have been approved; namely, challenges in access to these therapies, understanding potential effects of long-term treatment with newer therapies, and potential concerns with the use of these therapies in diseases with changing population demographics,” ScottRead More

Share on facebook
Share on twitter
Share on linkedin